Drug Trial Radar · NCT01480076
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
901
Actual
Start
Feb 2012
Primary completion
Jul 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Nov 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the effect of long-term treatment with prolonged-release fampridine (BIIB041) 10 mg twice daily on the physical component scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) as reported by treatment responders. The secondary objectives of this study are to compare the change in the PCS of the SF-36 between treatment responders and non-responders, to evaluate change from baseline in additional quality of life measures among treatment responders as well as changes from baseline in treatment responders versus non-responders and to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily.
Conditions
- Multiple Sclerosis
Interventions
FampridineDrug
Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: RespondersTime frame: Baseline, Months 3, 6, 9, 12
Locations
59 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Concord, New South Wales, Australia
Research Site
Kogarah, New South Wales, Australia
Research Site
Liverpool, New South Wales, Australia
Research Site
New Lambton Heights, New South Wales, Australia
Research Site
Auchenflower, Queensland, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Fitzroy, Victoria, Australia
Research Site
Heidelberg, Victoria, Australia
Research Site
Brasschaat, Belgium
Research Site
Brussels, Belgium
Research Site
Diepenbeek, Belgium
Research Site
Fraiture-en-Condroz, Belgium
Research Site
Ghent, Belgium
Research Site
Liège, Belgium
Research Site
Melsbroek, Belgium
Research Site
Overpelt, Belgium
Research Site
Sijsele-Damme, Belgium
Research Site
Wilrijk, Belgium
Research Site
Copenhagen, Denmark
Research Site
Paris, France
Research Site
Nice, Alpes-Maritimes, France
Research Site
Strasbourg, Bas-Rhin, France
Research Site
Caen, Calvados, France
Research Site
Bordeaux, Gironde 5, France
Research Site
Rennes, Ille-et-Vilaine, France
Research Site
Nantes, Loire-Atlantique 6, France
Research Site
Reims, Marne, France
Research Site
Clemont-Ferrand, Rhone, France
Research Site
Paris, Seine-Saint-Denis 14, France
Research Site
Amiens, Somme, France
Research Site
Berlin, Germany
Research Site
Erbach im Odenwald, Germany
Research Site
Hamburg, Germany
Research Site
Jena, Germany
Research Site
Osnabrück, Germany
Research Site
Schwendi, Germany
Research Site
Heidenheim, Bad Wuerttemberg, Germany
Research Site
Kassel, Hesse, Germany
Research Site
Oldenburg, Lower Saxony, Germany
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.